A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 5, 2009, Pages 562-568

  Fisher, Martin ^a   Moyle, Graeme J ^b   Shahmanesh, Mohsen ^c   Orkin, Chloe ^d   Kingston, Margaret ^e   Wilkins, Edmund ^f   Ewan, Jacqueline ^g   Liu, Hui ^g   Ebrahimi, Ramin ^g   Reilly, Geraldine ^g  

^a UK   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c SELLY OAK HOSPITAL   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^g GILEAD SCIENCES   (United States)

Author keywords

Combivir; Emtricitabine; Hemoglobin; HIV; Lamivudine; Lipids; Lipoatrophy; Switch; Tenofovir DF; Truvada; Zidovudine

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY FAT; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MORBIDITY; MORTALITY; MULTICENTER STUDY; NAUSEA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SLEEP DISORDER; STATISTICAL ANALYSIS; SYNCOPE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADENINE; ADIPOSE TISSUE; ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DEOXYCYTIDINE; EXTREMITIES; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LAMIVUDINE; LIPIDS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; YOUNG ADULT; ZIDOVUDINE;

EID: 68449101741     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ae2eb9     Document Type: Article

References (27)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patientswith advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
3. Duran S, Savès M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441-2444.
4. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
5. Moore R, Forney D. Anaemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:54-57.
6. Moyle G. The assessing patients' preferred treatments (APPT-1) study. Int J STD AIDS. 2003;14(Suppl 1):34-36.
7. Portsmouth S, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolongedrelease capsules. HIV Med. 2005;6:185-190.
8. Maitland D, Jackson A, Osorio J, et al. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med. 2008;9:667-672.
9. Dubé MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr. 2007;45:508-514.
10. Gallant JE, Staszewski S, Pozniak AL, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
11. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
12. Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147-155.
13. Moyle G, Sawyer W, Law M, et al. Changes in haematological parameters and treatment efficacy during thymidine analog-based HAART: a metaanalysis metaanalysis of 6 prospective randomized, comparative studies. Clin Ther. 2004;26:92-97.
14. Martin A, Smith D, Carr A, et al; for the Mitochondrial Toxicity (MITOX) Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-1036.
15. Moyle GJ, Baldwin C, Landroudi B, et al. A 48-week, randomized, openlabel comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.
16. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050.
17. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
18. Smith K, Fine D, Patel P, et al. Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study. CROI 2008, Boston, MA. 3-6 February, 2008. Abstract 774.
19. Martinez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290-297.
20. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
21. Lundgren J, Neuhaus J, Babiker A, et al. Use of Nucleoside Reverse Transcriptase Inhibitors and Risk of Myocardial Infarction in HIVInfected Patients Enrolled in the SMART Study. 17th International AIDS Conference, Mexico City, 3-8 August, 2008. Abstract THAB0305.
22. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect. 2005;51:E61-E65.
23. Quimby D, Brito MO. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read. 2005;15:357-364.
24. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37:1489-1495.
25. Mocroft A, Kirk O, Barton S, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999;13:943-950.
26. Levine A, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anaemia in a large cohort of HIV-infected women. Women's interagency HIV study. J Acquired Immune Defic Syndr 2001;28:26-28.
27. Semba R, Shah N, Klein R, et al. Prevalence and cumulative incidence of and risk factors for anaemia in a multicenter cohort study of HIV-infected and -uninfected women. Clin Infect Dis. 2002;34:260-266.